Hologic Inc Stock Price, News & Analysis

Hologic has announced a landmark multi-year partnership with the WTA, becoming the official health partner and global title sponsor of the WTA Tour. This represents the largest global sponsorship in WTA history and marks Hologic’s first worldwide sponsorship. The collaboration aims to promote women’s health and equality through initiatives that emphasize preventive care and healthy living. Hologic, known for its innovations in women’s health, will also support the creation of Hologic WTA Labs, focusing on health innovation for female athletes.

Hologic, Inc. (Nasdaq: HOLX) has announced its upcoming participation in two significant investor conferences. The first is Citi's 2022 Healthcare Services, Medtech, Tools & HCIT Virtual Conference scheduled for February 23 at 1:15 p.m. ET. The second is The Raymond James Institutional Investors Conference on March 8 at 9:50 a.m. ET. Both presentations will be webcast live and available for 30 days on Hologic's investor website.

Hologic focuses on enhancing women's health through early detection and treatment solutions.

Hologic (HOLX) reported Q1 2022 revenue of $1.471 billion, down 8.6% year-over-year, notably exceeding prior guidance of $1.1-$1.15 billion. GAAP diluted EPS was $1.95 while non-GAAP diluted EPS was $2.17, both below last year's figures. Organic revenue grew 9% excluding COVID sales, with Breast Health and GYN Surgical divisions each above 8% growth. The company significantly raised its full-year revenue guidance by $600 million and non-GAAP EPS by $1.35. Cash flow from operations remained robust at $564.2 million.

Hologic (Nasdaq: HOLX) has unveiled its first national direct-to-consumer advertising campaign, launching during the 'Big Game' on NBC on February 13, 2022. The campaign, titled "Her Health is Her Wealth", features Mary J. Blige and aims to promote preventive screenings for women, emphasizing the importance of regular health check-ups that many missed during the COVID-19 pandemic. Research indicates that nearly 50% of women aged 16-54 have not had a health screening in the past year. The campaign will also include digital activations via ScreeningsForHer.com.

Hologic, Inc. (NASDAQ: HOLX) reported preliminary revenue of $1,471.1 million for Q1 fiscal 2022, exceeding guidance of $1,100 to $1,150 million. This represents an 8.6% decline year-over-year. Organic revenue, excluding COVID-19 benefits, grew 9%, with all divisions showing over 8% growth. The Diagnostics division contributed $950.4 million, despite a 15.8% drop from the previous year. Non-GAAP diluted EPS is expected to exceed guidance of $1.15 to $1.25. Full Q1 results are set for release on February 2, 2022.

Hologic, Inc. (NASDAQ: HOLX) will release its financial results for Q1 Fiscal 2022 on February 2, 2022, after market close. Management will host a conference call at 4:30 p.m. ET the same day. Interested participants can join by dialing specified numbers or via a live webcast on the company's website. A replay will be available until February 25, 2022. Hologic is dedicated to enhancing women's health through innovative medical technology solutions.

Hologic, Inc. (NASDAQ: HOLX) has expanded its Global Access Initiative (GAI) to include the Aptima® SARS-CoV-2 assay, aimed at improving access to COVID-19 diagnostics in resource-limited countries. The GAI, launched in 2018, facilitates affordable diagnostic testing without upfront costs. Hologic has already provided over 700,000 SARS-CoV-2 tests during the pandemic, partnered with organizations like WHO and UNICEF. This expansion enhances accessibility and reflects Hologic's commitment to equitable health systems worldwide.

Hologic, Inc. (NASDAQ: HOLX) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 p.m. Eastern Time. The presentation and Q&A session will be webcast live and accessible through Hologic’s investor website. The webcast will remain available for 30 days post-event. Hologic focuses on enhancing women's health through early detection and treatment technologies. For further details, visit www.hologic.com.